Oncimmune Holdings PLC Investor Presentation via Investor Meet Company (5711Q)
19 October 2023 - 5:00PM
UK Regulatory
TIDMONC
RNS Number : 5711Q
Oncimmune Holdings PLC
19 October 2023
19 October 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Investor Presentation via Investor Meet Company
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
is pleased to announce that Martin Gouldstone, Chief Executive
Officer, and Martin Hudson, Finance Director, will provide a live
presentation relating to the Company's updated strategy, as
announced on 12 October 2023, via Investor Meet Company on 25
October 2023 at 12.00pm BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Oncimmune Holdings plc via:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Investors who already follow Oncimmune Holdings plc on the
Investor Meet Company platform will automatically be invited.
For further information:
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a global leader in immune biomarkers and
immunodiagnostics, offering autoantibody biomarker profiling in
immunooncology, autoimmune and infectious diseases. Through its
ImmunoINSIGHTS(TM) technology platform, the Company provides
insights and analytics to discover and validate novel biomarkers,
improve treatment responses and adverse event (irAE) prediction,
patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK, with its discovery and
development facility based in Dortmund, Germany and a business
development team based in the US and Europe.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBSBDGGXBDGXI
(END) Dow Jones Newswires
October 19, 2023 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024